<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23843">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796391</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18671</org_study_id>
    <nct_id>NCT02796391</nct_id>
  </id_info>
  <brief_title>Facilitating Smoking Cessation With Reduced Nicotine Cigarettes</brief_title>
  <official_title>Facilitating Smoking Cessation With Reduced Nicotine Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James and Esther King Biomedical Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if targeted interventions will help people to stop or
      reduce smoking better than standard interventions using very low nicotine content (VLNC)
      cigarettes.

      This developmental pilot study (n=20) will determine the feasibility of the treatment
      approach and methodology, and lead to refinements for a subsequent randomized controlled
      trial (RCT).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study 1 - Rate of Participant Completion of Pilot</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Complete formative research based on 20 participants, 10 per study arm to prepare for Study 2.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Study 2 - Rate of 5 Day Abstinence Success</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The purpose of Study 2 will be to test effects of the targeted intervention developed in Study 1 on smoking cessation. Participants will report success, or lack thereof, in remaining abstinent during five daily abstinence verification visits.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Lowest Nicotine Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gradual Decreasing Nicotine Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Very Low Nicotine Content (VLNC) Cigarettes</intervention_name>
    <description>Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week. Participants will be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group.</description>
    <arm_group_label>Lowest Nicotine Dose</arm_group_label>
    <arm_group_label>Gradual Decreasing Nicotine Dose</arm_group_label>
    <other_name>SPECTRUM®</other_name>
    <other_name>Research Cigarettes</other_name>
    <other_name>NOT-DA-13-002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  smoke at least 5 cigarettes daily for the past year

          -  expired-air carbon monoxide (CO) &gt; 8 ppm (if ≤ 8 ppm, then NicAlert Strip &gt; 2)

          -  current motivation to quit smoking

          -  able to speak and read English sufficiently for completion of consent form and
             questionnaires

        Exclusion Criteria:

          -  pregnant or breastfeeding

          -  significant unstable medical/psychiatric or substance use disorders, or
             medically/psychiatrically at risk in the judgment of the study physician or principal
             investigator (PI)

          -  positive urine screen for cocaine, opiates, methadone, benzodiazepines, barbiturates,
             amphetamines, methamphetamines, or PCP (NOTES: THC will be tested but will not be an
             exclusionary criterion; participants with valid prescriptions for opiates,
             benzodiazepines, barbiturates, amphetamines or methadone will not be excluded;
             participants failing the toxicology screen will be allowed to re-screen once)

          -  blood alcohol level &gt; 0.01 (one re-screen allowed)

          -  binge alcohol drinking (4/5 [female/male] drinks per day more than 9 days in the past
             month)

          -  systolic/diastolic blood pressure (BP) greater than or equal to 160/100, or below
             90/50 (one re-screen allowed)

          -  heart rate greater than or equal to 115 beats per minute (bpm), or below 45 bpm (one
             re-screen allowed)

          -  ever used reduced nicotine cigarettes

          -  smoke 'roll your own' cigarettes exclusively

          -  used smoking cessation medications within the past three months

          -  used other tobacco products more than 9 days in the past month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Drobes, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gazelle Rouhani</last_name>
      <phone>813-745-1127</phone>
      <email>gazelle.rouhani@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>David Drobes, Ph.D.</last_name>
      <phone>813-745-4953</phone>
      <email>david.drobes@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Drobes, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Brandon, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Evans, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Roetzheim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vani Simmons, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>June 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>cigarettes</keyword>
  <keyword>very low nicotine content (VLNC)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
